Merck Urges Shareholders to Reject Deep-Discount Mini-Tender Offer
MT Newswires Live
Nov 24
Merck (MRK) said late Friday that shareholders should not participate in the unsolicited mini-tender offer launched by Tutanota at $65 per share, which is well below recent market prices.
The company said Tutanota plans to buy up to 1 million of its shares, at a price more than 31% below last Thursday's closing level.
The drugmaker added that shareholders should also refrain from participating due to the numerous conditions attached to the offer and Merck's lack of any affiliation with Tutanota.
Investors who have already tendered their shares may withdraw them before the offer expires on Dec. 15.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.